ABCD1 and X-linked adrenoleukodystrophy: Intravenous or intracerebroventricular administration of AAV9-delivered exogenous ABCD1 can achieve continuous expression of ABCD1, but in concentrations that are inconsistent with those of endogenous ABCD1, which is suboptimal for treating X-ALD.